Background HIV antiretroviral therapy (ART) is often managed without routine laboratory monitoring in Africa; however, the eff ect of this approach is unknown. This trial investigated whether routine toxicity and effi cacy monitoring of HIV-infected patients receiving ART had an important long-term eff ect on clinical outcomes in Africa.
Introduction
The unprecedented expansion of antiretroviral therapy (ART) in Africa has been achieved in settings with poor health infrastructure, and often without access to routine laboratory monitoring for toxic eff ects or effi cacy. Whether treatment programmes should provide laboratory monitoring or focus resources on continuing to expand access to fi rst-line and second-line ART is a crucial debate in the present economic crisis. 1, 2 In resource-rich countries, patients receiving ART have routine (typically every 3 months) tests to monitor effi cacy and toxic eff ects. This testing is not mandated in public health ART rollout 3 -the approach underpinning many African treatment programmes-because it needs high-technology laboratory services and substantial resources. In fact, the eff ect of routine laboratory monitoring, in addition to good clinical care, has been formally assessed only in one trial in Uganda (data not published 4 ). This information is crucial for policy makers and implementers. If routine laboratory tests do not add signifi cant benefi t, ART programmes would be open to decentralisation with long-term follow-up in local clinics rather than distant hospitals, providing that con sistent and good quality care could be provided. Laboratory services could be targeted to assessment for ART eligibility and to diagnosis and management of opportunistic infec tions or clinical toxicity, rather than being done routinely.
The Development of AntiRetroviral Therapy in Africa (DART) trial was therefore designed to investigate whether delivery of ART with or without routine monitoring of CD4-cell counts for effi cacy, and haematology and biochemistry for safety, led to similar outcomes in HIVinfected patients receiving ART who had already fulfi lled clinical and CD4-count criteria to start ART.
Methods

Study design and participants
DART was an open randomised trial enrolling symptomatic (WHO stage 2-4) HIV-infected adults (≥18 years) with CD4 counts less than 200 cells per μL who reported no previous ART apart from to prevent mother-to-child transmission. Participants were enrolled between Jan 15, 2003, and Oct 24, 2004 and satellite Infectious Diseases Institute, Mulago) and Zimbabwe (University of Zimbabwe, Harare). Exclusion criteria were: cannot, or unlikely to attend regular follow-up (eg, usual residence too far from study centre); likelihood of poor compliance; presence of acute infection (patients could be admitted after recovery of an acute infection) or on intensive phase of antituberculosis therapy; receiving chemotherapy for malignant disease; laboratory abnormalities that were a contraindication for the patient to start ART (eg, haemoglobin concentration <80 g/L, neutrophils <0·50×10⁹/L, alanine amino trans ferase [ALT] or aspartate aminotransferase [AST] more than fi ve times the upper limit of normal, grade 3 renal dysfunction [creatinine >360 μmol/L or urea more than fi ve times the upper limit of normal]); and pregnancy or breastfeeding. Participants gave written consent both for screening and, if eligible, enrolment. The trial was approved by research ethics committees in Uganda, Zimbabwe, and the UK.
Randomisation and masking
At enrolment all participants received triple-drug ART (coformulated zidovudine-lamivudine [GlaxoSmithKline, Ware, UK] plus tenofovir disoproxil fumarate [Gilead Science, Foster City, CA, USA], abacavir [GlaxoSmithKline, Ware, UK], or nevirapine [Boehringer Ingelheim, Ingelheim, Germany]) and were randomly assigned to receive clinically driven monitoring (CDM) or laboratory plus clinical monitoring (LCM) for toxic eff ects (haematology and biochemistry) and effi cacy (CD4-cell counts). HIV viral loads were not done in real-time, in accordance with WHO guidelines 5 and national norms. The hypothesis was that CDM would result in similar outcomes to LCM (non-inferiority). 600 participants were randomly assigned to diff erent fi rst-line ART regimens in the nested Nevirapine OR Abacavir (NORA) substudy (placebo-controlled to NORA primary endpoint of toxicity at 24 weeks 6 ); all other participants received open-label fi rst-line ART. A further partial factorial randomisation within DART comparing structured treatment interruptions with continuous ART in 813 participants with CD4 counts greater than 300 cells per μL after 48 or 72 weeks on continuous ART ended in March, 2006. 7 Randomisation was stratifi ed by centre, screening CD4 count (0-99 vs 100-199 cells per μL), and fi rst-line ART (tenofovir disoproxil fumarate vs nevirapine vs randomisation in NORA). The computer-generated sequentially numbered randomisation list (with variable block sizes) was preprepared by the trial statistician and securely incorporated within the database at each trial centre, connected to but not located within each clinical centre, allowing trial managers to access the next number but not the whole list. Randomisation was undertaken by clinicians phoning the local trials centre.
Procedures
All participants saw a doctor and had a routine full blood count with white cell diff erential, lymphocyte subsets (CD4, CD8), and liver and renal function tests (bilirubin, urea, creatinine, AST/ALT) at screening, weeks 4 and 12, and then every 12 weeks. All results for LCM participants were returned to clinicians, whereas results after enrolment for CDM participants were returned only if requested for clinical reasons (reviewed and authorised 
Figure 1: Trial profi le
CDM=clinically driven monitoring. LCM=laboratory and clinical monitoring. ART=antiretroviral therapy. *Main reason for ineligibility. †221 (55%) participants subsequently returned and were rescreened. ‡One participant had taken ART before starting the trial, and was not prescribed trial drugs or followed up; one individual without a consent form at monitoring defaulted before 8 weeks.
by each centre project leader) or if there was grade 4 laboratory toxic eff ects (protocol safety criteria, grades defi ned in protocol according to minor modifi cations of the AIDS Clinical Trials Group criteria 8 ). No total lymphocyte or CD4-cell counts were returned for participants assigned to CDM. For all participants, diagnostic investigations and other laboratory tests (apart from CD4-cell count and total lymphocytes for CDM) could be requested, and concomitant drugs prescribed, as clinically indicated. All participants received ART and were reviewed by a nurse every 4 weeks (with use of a standard symptom checklist).
Antiretroviral drugs could be substituted, preferably within class, for adverse events. The decision to switch to second-line ART (with a ritonavir-boosted protease inhibitor) was based on clinical criteria in both groups (new or recurrent WHO stage 4 event; or WHO stage 3 event such as candidosis or weight loss at clinician discretion), or on laboratory criteria for LCM (confi rmed CD4 count <100 cells per μL on ART [<50 cells per μL before July, 2006]). Following WHO guidelines, 9 switching before 48 weeks was discouraged.
Participants were followed up under CDM or LCM strategies until Dec 31, 2008. At their next visit in January, 2009, participants assigned to CDM received all masked results, and those with low CD4-cell counts (following WHO guidelines 9 ) were switched to second-line ART.
Study outcomes
The co-primary endpoints were (1) progression to a new WHO stage 4 HIV event or death, 10 and (2) serious adverse events, which were defi ned as events not related only to HIV and either fatal, life-threatening, causing unplanned or prolonged admission to hospital, causing permanent or signifi cant disability, or other important medical conditions. 11 Laboratory or clinical grade 4 adverse events did not have to be reported as serious adverse events unless they met one of these criteria. Secondary endpoints were: mortality; progression to a new or recurrent WHO stage 4 HIV event or death; any grade 3 or 4 adverse events; number and class of antiretroviral drugs received; time to second-line regimen; adherence measured by questionnaire and pill counts; CD4-cell counts; HIV RNA viral load and resistance (done retrospectively); and cost-eff ectiveness (reported separately). All WHO stage 4 events, deaths, and serious adverse events were reviewed against prespecifi ed criteria by an Endpoint Review Committee with an independent chair and members, all of whom were masked to randomised allocation.
Statistical analysis
Interim data for safety, adherence to randomised strategies, and effi cacy of CDM and LCM were reviewed regularly by an independent Data Safety and Monitoring Committee, which met every 9-12 months (seven meetings in total). The Haybittle-Peto criterion, p<0·001, 12 was the statistical guide for considering recommending stopping or modifying the trial.
The planned sample size of 3300 adults followed up for 4-6 years provided 80% power to establish that CDM was not inferior to LCM. Non-inferiority was defi ned as the upper 95% confi dence limit for the hazard ratio (HR; CDM:LCM) for new WHO stage 4 events or death being no greater than 1·18, which is equivalent to a yearly rate of progression of no more than 11·8 per 100 person-years in CDM compared with a predicted rate of 10·0 per 100 person-years in LCM. 
Table: Characteristics at randomisation (ART initiation)
Kaplan-Meier plots, log-rank test, and proportional hazards models, stratifi ed by randomisation stratifi cation factors, were used to compare randomised groups for time-to-event outcomes, censoring at the earlier of Dec 31, 2008, or last follow-up. Categorical variables were com pared between randomised groups with χ² or exact tests, and continuous variables with t tests or rank-sum tests. All comparisons between groups were as ran domised (intention to treat). Baseline values were those nearest to but before and within 42 days of randomisation. Generalised estimating equations (independent corre la tion structure) were used to compare laboratory measure ments and adherence across randomised groups over time, with the closest measurement to each scheduled visit within equally spaced intervals. All p values are two-sided.
This study is registered, number ISRCTN13968779.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. 3321 participants were enrolled. Three participants randomised twice (at diff erent centres) were included from their fi rst randomisation, and two with major eligibility violations were excluded, leaving 3316 participants in the fi nal intention-to-treat analysis (fi gure 1). Baseline characteristics were similar between groups (table) . Clinicians managing participants assigned to CDM could request individual results from the routine biochemistry or haematology panels (every 12 weeks) for clinical reasons. These haematology or biochemistry panels could also be requested, if clinically indicated, at inter vening nurse visits every 4 weeks and extra patientinitiated visits in both groups. Most of the tests done from these panels were undertaken at routine visits every 12 weeks (<8% at nurse/extra visits for haematology and <5% for biochemistry panels; webappendix p 1). In the CDM group, very few (<4%) individual results were released (webappendix p 1), most often haemoglobin, neutrophils, creatinine, and urea. Overall, more additional investigations were requested during nurse or extra visits in the LCM group than in the CDM group: 812 (49%) participants assigned to CDM and 965 (58%) to LCM had one or more additional haematology tests (p<0·0001); and 639 (38%) assigned to CDM and 683 (41%) to LCM had one or more additional biochemistry tests (p=0·11). 635 (38%) CDM and 633 (38%) LCM participants had one or more other (non-routine panel) blood tests (p=0·99), mostly other biochemistry (eg, electrolytes).
Results
At Dec 31, 2008, or last clinic visit, 1346 (81%) people receiving CDM versus 1295 (78%) receiving LCM were still on fi rst-line ART, including 288 (17%) CDM and 281 (17%) LCM participants who had substituted one or more fi rst-line drugs (rates 7·4 [95% CI 6·8-7·5] and 7·6 [7·0-8·3] per 100 person-years, respectively). Adverse events led to 859 of 1037 (83%) fi rst-line substitutions (427 in CDM group and 432 in LCM group; participants could substitute more than once in fi rst-line treatment), with the remainder due to concomitant anti tuberculosis therapy (81 [8%]; 44 in CDM group and 37 in LCM group) or other reasons (eg, pregnancy; data not shown). Adherence by self-reported questionnaire every 4 weeks was similar in both groups, with 3·5% (3164/90 233) reports in the CDM group versus 3·3% (2995/91 979) in the LCM group of missing pills in the last 4 days (p=0·14), and 8·5% (7692/90 929) versus 7·8% (7256/92 656) in the last 28 days (p=0·45). 
Figure 3: Clinical disease progression (A) and adverse events (B)
All hazard ratios were stratifi ed according to randomisation factors, and p values were calculated with the log-rank test. Number needed to monitor for 1 year to avoid one (fi rst) event was 130 (death) and 59 (new WHO stage 4 event of death) participants. Survival p values were 0·95 at 1 year, 0·92 at 3 years, and 0·90 at 5 years for laboratory and clinical monitoring (LCM) group; 0·94, 0·90, and 0·87 for clinically driven monitoring (CDM) group; and 0·55, 0·18, and 0·08 for the Entebbe 15 cohort, respectively. HR=hazard ratio. ART=antiretroviral therapy. *Data from HIV-infected population of similar disease stage between 1996 and 2000.
151 of 314 (48%) CDM versus 145 of 361 (40%) LCM participants had CD4 count less than 50 cells per μL; 64 (20%) CDM participants who switched did so with CD4 counts greater than 250 cells per μL compared with only seven (2%) LCM participants. Despite large diff erences in the number of laboratory toxicity tests in the two groups, the proportion of participants having one or more serious adverse events (co-primary endpoint) was similar (283 [17%] in CDM group vs 260 [16%] in LCM group; fi gure 3). The most common type was hospital admissions (266/650 serious adverse events: 155 in CDM and 111 in LCM groups), and the most common diagnosis was anaemia (137/650 serious adverse events: 76 in CDM and 61 in LCM groups, webappendix p 2). 422 (25%) CDM participants and 416 (25%) LCM participants had adverse events leading to fi rst-line or second-line ART modifi cation (HR 1·01 [95% CI 0·88-1·16]; p=0·86), with anaemia the most common cause (312/1252 modifi cations; 173 in CDM group vs 139 in LCM group) followed by lipodystrophy or lipoatrophy (113 vs 128) 
Discussion
DART was designed as a large non-inferiority trial with suffi cient power to establish whether routine toxicity and effi cacy monitoring on ART had an important long-term eff ect on clinical outcomes in Africa. The results clearly show that fi rst-line ART can be delivered safely without routine biochemistry and haematology monitoring for toxic eff ects, but that routine CD4-cell count monitoring has a small but signifi cant benefi t in terms of disease progression and mortality, probably owing to slightly earlier switching to second-line ART.
In the original trial design, clinically relevant inferiority was predefi ned as a small increase in new WHO stage 4 events or death from 10 per 100 person-years in the LCM group to 11·8 per 100 person-years in the CDM group. To show that the eff ect of CDM was no more than this increase was regarded as an acceptable defi nition of non-inferiority; given the likely costs of routine laboratory monitoring, small diff erences would be unlikely to be cost eff ective and given the potential of CDM to allow wider ART rollout in Africa. CDM was clearly not non-inferior, with a signifi cant increase recorded in disease progression and death. However, since the 95% CI for the co-primary endpoint new WHO stage 4 event or death included our predefi ned non-inferiority margin, we also cannot formally state that CDM was inferior.
CDM in DART was not implemented as no laboratory monitoring-all participants had a CD4-cell count done to establish eligibility for ART, and participants assigned to CDM could have investigations and blood tests (apart from CD4-cell count) that are necessary to manage clinical episodes, as could be feasible outside a trial setting. Indeed, with well supervised and supported clinical care that is freely available to participants, 87% survival at 5 years was achieved in the CDM group-much better than predicted given that a third of participants had CD4 count less than 50 cells per μL at ART initiation, and among the best reported in Africa [16] [17] [18] and worldwide. 19, 20 This fi nding clearly shows that good ART outcomes with low mortality can be attained without routine laboratory monitoring.
Irrespective of monitoring strategy, overall survival at 5 years was 88% (death rate 2·56 per 100 person-years). The huge survival benefi ts from ART are well documented by historical comparison within the Entebbe centre 17 (fi gure 3). More than 80% of participants started ART with triple nucleoside reverse transcriptase inhibitors, allaying concerns that these regimens have suboptimum clinical effi cacy. High loss to follow-up can underestimate mortality, but with the very high retention sustained through 6 years, we are confi dent that the trial results are robust. Although quality of care might vary between ART programmes, and rarely matches that provided in well resourced clinical trials, we see no reason why the additional eff ect of routine laboratory monitoring should depend on the level of care provided. If anything, the interpretation of routine laboratory results by less well trained and supervised health-care workers with little access to diagnostic services and in-patient facilities would tend to weaken the usefulness of the results and provide relatively less benefi t than the small diff erences recorded here. Routine haematology and biochemistry toxicity laboratory monitoring did not aff ect time to fi rst serious adverse event, grade 3-4 or 4 adverse event, or ART-modifying toxic eff ects. First-line substitution rates were similar across groups, with about 20% of participants using alternative or substituted fi rst-line regimens at 5 years. These results should be generalisable to all currently used fi rst-line regimens, given that stavudine toxic eff ects are mostly clinical (ie, would not be likely to be aff ected by routine laboratory monitoring for toxic eff ects) and that more than 900 DART participants took nevirapine, 547 from the start of ART. The number of additional tests done was generally greater in the LCM group than in the CDM group, suggesting that routine monitoring promotes, rather than prevents, extra tests being done.
Routine effi cacy monitoring with CD4 tests every 12 weeks had no discernible eff ect in the fi rst year on ART, but resulted in higher rates of switch to second-line therapy from the second year on ART, small but signifi cant decreases in the proportion of person-years spent with low CD4-cell counts, and lower rates of HIV disease progression and death from the third year on ART (but not before) than in CDM. Of note, a fi fth of participants assigned to CDM with clinically-identifi ed failure had CD4 counts greater than 250 cells per μL, confi rming previous reports that laboratory and clinical failure criteria do not always agree. 21, 22 Although small compared with the eff ect of ART, the identifi ed benefi ts of CD4-cell count monitoring are highly unlikely to be attributable to chance, and further assessment of less frequent CD4 measurements (eg, every 6 months) and targeted CD4cell counts to confi rm immunological failure at suspected clinical failure is needed. All DART participants had CD4cell counts measured before ART initiation and were screened for haematological and biochemical abnormalities. DART cannot therefore inform the debate about use of CD4-cell counts to establish eligibility for ART or the value of routine pre-ART laboratory screening.
In a parallel, individual-patient, cost-eff ectiveness analysis (data not published), routine laboratory monitoring every 12 weeks for toxic eff ects was particularly expensive. In the LCM group, early switching to second-line ART, although lowering costs of hospital admissions, resulted in signifi cantly greater costs of second-line drugs. Therefore overall costs of CDM were much lower than were those of LCM, and LCM, as implemented in DART, was not cost eff ective on the basis of present WHO recommendations for sub-Saharan Africa of three times gross domestic product per head 23 -about US$1200 in Uganda and Zimbabwe. Further continuing sensitivity analyses are exploring the cost-eff ectiveness of scenarios, including routine CD4cell count but not laboratory monitoring for toxic eff ects while on ART. If budget constraints necessitate choices in where best to allocate scarce resources, our data suggest that a greater public health eff ect would be gained from widening access to ART for untreated patients with low CD4-cell counts who are at high risk of mortality rather than providing routine laboratory monitoring for people already receiving ART.
DART has several potential limitations. Randomisation was open, although members of the Endpoint Review Committee were masked to allocation. Although clinicians were encouraged to report all potential endpoints, WHO stage 4 events might have been under-reported in LCM participants with higher CD4-cell counts; however, this would reduce diff erences between groups in event-free survival. In the few instances in which CDM participants reported obtaining external CD4-cell counts during the trial, clinicians remained masked. In a survey at DART exit, only 81 of 1281 (6%) CDM participants reported having CD4-cell counts done privately, half having only one test. Finally, real-time viral load testing was not feasible when DART started. Detailed analyses of viral load and resistance assays undertaken on stored specimens are in progress, and will inform the debate about how best to use these tests in ART programmes in Africa.
Few studies are available with which to compare DART results. The randomised HBAC trial compared clinical monitoring with CD4-cell monitoring and with CD4-cell plus virological monitoring in more than 900 patients followed up for 3 years. 4 Investigators reported that the use of routine CD4-cell count monitoring was associated with fewer new AIDS-defi ning events or death than was clinical monitoring alone, which is a similar fi nding to DART. However, switching rates were highest in the clinical group, making interpretation diffi cult. A modelling study also projected very small diff erences between virological, CD4-cell count, and clinical monitoring strategies to 5 years. 24 DART results have major implications for ART programmes in Africa at a time when there is uncertainty about long-term funding and sustainability and when most people still cannot access treatment. 25 We have shown that routine laboratory monitoring for toxic eff ects in HIV patients receiving ART has no benefi t. ART can be delivered safely with good quality clinical care, allowing treatment delivery to be decentralised. Small diff erences in disease progression suggest a role for CD4-cell testing from the second year on ART to guide the switch to second-line ART and should encourage accelerated development of simpler, cheaper, point-of-care CD4 tests. Laboratories will remain important for assessment of eligibility for ART, in terms of CD4-cell count and contraindications for specifi c drugs, and for diagnosis and management of opportunistic infections and clinical toxicity. With less need to provide routine monitoring, particularly for toxicity, funding can be focused on drug procurement, strengthening of diagnostic laboratory services, and training and supervision for health-care workers to foster quality clinical monitoring, to support scale-up of ART rollout to rural Africa where 60% of the HIV-infected population live.
